ORAPRED ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAPRED ODT (ORAPRED ODT).
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory and immunosuppressive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; prednisolone is the active metabolite of prednisone. |
| Excretion | Primarily renal (80-90% as inactive glucuronide and sulfate conjugates; less than 10% as unchanged drug). Biliary/fecal excretion accounts for about 5%. |
| Half-life | Terminal elimination half-life: 2-3 hours (after IV/IM/oral). Clinically, anti-inflammatory effects persist beyond plasma half-life due to glucocorticoid receptor-mediated gene transcription effects. |
| Protein binding | 90-95% primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd: 0.5-0.8 L/kg (approx 35-56 L in 70 kg adult). Indicates distribution into total body water, readily penetrates tissues including central nervous system. |
| Bioavailability | Oral: 70-90% (well absorbed). Intravenous: 100%. Rectal (enema): variable, about 30-50% of oral. |
| Onset of Action | Oral: 1-2 hours (peak effect at 1-2 hours). Intravenous: within 2-30 minutes. Intra-articular: 1-2 days. |
| Duration of Action | Oral: biological duration of action is 1-2 days (due to receptor-mediated effects). Clinical duration of anti-inflammatory effect: 2-3 days after single dose. Intra-articular: 2-3 weeks. |
| Molecular Weight | 360.44 |
10-60 mg orally once daily or divided twice daily; maximum 60 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No adjustment necessary; drug is metabolized in liver. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 0.5-2 mg/kg orally per day in divided doses every 12 hours; maximum 60 mg/day. |
| Geriatric use | Start at lower end of dosing range; monitor for fluid retention, hyperglycemia, and osteoporosis. |
| 1st trimester | Use during first trimester is generally avoided due to known teratogenic effects of corticosteroids, including orofacial clefts. Animal studies have shown an increased risk of cleft palate. Human data are limited, but risk cannot be excluded. Use only if clearly needed and no alternative exists. |
| 2nd trimester | Use during second trimester may be considered if benefit outweighs risk. Chronic use may lead to intrauterine growth restriction and adrenal suppression in the neonate. Monitor fetal growth with ultrasound if long-term therapy is required. |
| 3rd trimester | Use during third trimester carries risk of neonatal adrenal suppression if used near term. Also associated with premature rupture of membranes and increased risk of infection. Use only if necessary and consider tapering prior to delivery. |
Clinical note
Comprehensive clinical and safety monograph for ORAPRED ODT (ORAPRED ODT).
| Placental transfer | Prednisolone crosses the placenta, but is partially inactivated by 11β-hydroxysteroid dehydrogenase type 2. Approximately 10-15% of maternal dose reaches fetus. Transfer is higher for prednisone compared to prednisolone due to conversion in placenta. |
■ FDA Black Box Warning
Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles, and if exposed, to seek medical advice.
| Serious Effects |
Systemic fungal infectionsAdministration of live or live attenuated vaccines (due to immunosuppression)Hypersensitivity to prednisolone or any component of the formulation
| Precautions | Increased risk of infections due to immunosuppression, Adrenal suppression and insufficiency upon withdrawal, Masking of signs of infection, Increased risk of GI perforation in certain conditions, Osteoporosis with prolonged use, Growth suppression in children |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing prednisolone exposure. High-sodium foods may exacerbate fluid retention and hypertension. Alcohol may increase gastrointestinal irritation. Maintain adequate calcium and vitamin D intake to prevent osteoporosis with long-term use. |
Loading safety data…
| Breastfeeding | Prednisolone is excreted into breast milk in low concentrations. Doses up to 40 mg daily are unlikely to cause systemic effects in the infant. However, if high doses (>40 mg) are used, advise pumping and discarding milk for 4 hours after dose to minimize infant exposure. Monitor infant for signs of adrenal suppression (poor feeding, lethargy, vomiting) with prolonged maternal use. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Orapred ODT (prednisolone sodium phosphate) is a corticosteroid. First trimester: Increased risk of cleft palate (odds ratio 3.4). Second trimester: Possible intrauterine growth restriction. Third trimester: Risk of adrenal suppression in neonate. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal ultrasound for growth restriction. Assess neonatal adrenal function if used in late pregnancy. |
| Fertility Effects | No known adverse effect on fertility in humans. In animal studies, high doses caused impaired spermatogenesis; relevance unknown. |
| Clinical Pearls | Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is a corticosteroid with rapid onset due to its water-soluble salt form. It dissolves on the tongue without water, aiding compliance in children. Dosing should be individualized based on severity and response; abrupt discontinuation after prolonged use can cause adrenal insufficiency. Monitor for hyperglycemia, hypertension, and immunosuppression. Do not break or split tablets; ensure oral mucosa is intact for sublingual absorption. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without doctor's guidance as it may cause withdrawal symptoms. · The tablet dissolves on the tongue; do not chew or swallow whole. Ensure mouth is dry before placing tablet. · Avoid grapefruit and grapefruit juice during treatment as they may increase side effects. · Report signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately. · This drug can raise blood sugar; monitor if diabetic and inform healthcare provider of any vision changes or increased thirst/urination. · Avoid live vaccines while on this medication. · May cause dizziness or blurred vision; avoid driving until you know how it affects you. |